search
Back to results

Study of Acid Reflux in Asthma

Primary Purpose

Asthma, Lung Diseases, Lung Diseases, Obstructive

Status
Completed
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
Esomeprazole
Placebo proton pump inhibitor
Sponsored by
Johns Hopkins Bloomberg School of Public Health
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Asthma

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: The general goal of patient selection is to enroll patients for whom asthma physicians might prescribe GERD treatment, but where there is uncertainty whether it might be effective. Age 18 or older Physician diagnosed asthma If amount of air expired in the first second during a forced expiratory maneuver (FEV1) is greater than or equal to 70% predicted normal pre-bronchodilator: demonstrate methacholine 20% from post-diluent baseline (PC20). PC20 less than 16 mg/ml during Visit 1 If FEV1 less than 70% and greater than or equal to 50% predicted normal pre-bronchodilator: demonstrate 12% reversibility during Visit 1 or within past 12 months Currently on stable dose of daily inhaled steroids for asthma control, i.e., inhaled corticosteroid equivalent to 400 ug/day of fluticasone44 or greater for 8 weeks or longer Poor asthma control: Either of the following; a score of 1.5 or greater on the Juniper Asthma Control Questionnaire; two or more episodes of asthma symptoms in the past 12 months with each episode requiring at least one of the following: an emergency department visit, unscheduled physician visit, prednisone course, hospitalization Non-smoker for 6 months or longer Less than 10 pack/year smoking history Exclusion Criteria: Surgery: Previous anti-reflux or peptic ulcer surgery Pulmonary function: FEV1 less than 50% predicted normal pre-bronchodilator GERD Symptoms: Severe reflux constituting a clinical indication for treatment with a PPI or H2 blocker, typically two or more episodes per week of heartburn requiring antacids Other major chronic illnesses; conditions which in the judgment of the Study Physician would interfere with participation in the study, e.g., non-skin cancer, endocrine disease, coronary artery disease, congestive heart failure, stroke, severe hypertension, Type 1 insulin dependent diabetes mellitus, renal failure, liver disorders, immunodeficiency states, major neuropsychiatric disorder Medication use: Anti-reflux medication (proton pump inhibitors or H2 blockers) within 1 month Theophylline, azoles, iron, anti-coagulants, insulin (for Type I diabetes), digitalis, any investigative drugs within 1 month Drug allergy: Previous adverse effects from proton pump inhibitors or methacholine challenge Females of childbearing potential: Pregnant or lactating, unwilling to practice an adequate birth control method (abstinence, combination barrier and spermicide, or hormonal) Inability or unwillingness to provide consent Inability to perform baseline measurements Completion of less than 10 of the last 14 days of screening period diary entry Inability to be contacted by telephone Intention to move out of the area within 6 months

Sites / Locations

  • University of Alabama at Birmingham
  • University of California, San Diego
  • National Jewish Medical and Research Center
  • Nemours Childrens Clinic
  • University of Miami
  • Emory University
  • Northwestern Memorial Hospital
  • Indiana University ACRC
  • LSUHSC Pulmonary Critical Care
  • University of Minnesota
  • Univ of MO Kansas City School of Medicine
  • Washington University School of Medicine
  • North Shore-LIJ Medical Center
  • NYU School of Medicine
  • New York Medical College
  • Duke University
  • Ohio State University
  • Thomas Jefferson Hospital Pulmonary Lab
  • Baylor College of Medicine
  • Northern New England Consortium

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Esomeprazole

Placebo for esomeprazoe

Arm Description

Proton pump inhibitor of gastric acid

Placebo

Outcomes

Primary Outcome Measures

Episodes of Poor Asthma Control (EPAC) From Diary Cards, According to Definition That Did Not Include Use of Beta-agonists as a Criterion
Episodes of poor asthma control was defined as any one of the following: 2 consecutive days with a drop in peak flow >=30% of baseline; urgent care for asthma; or new use of oral corticosteroids for asthma

Secondary Outcome Measures

Exacerbation Components: >=30% Drop in Peak Expiratory Flow on 2 Consecutive Days
Exacerbation Components: Urgent Care Visit
Exacerbation Components: New Use of Oral Corticosteroids
Asthma Episodes, According to Definition That Included Increased Use of Beta-agonists
Use of Rescue Medications
Increase in the use of rescue meds by 4 or more uses on a particular day above the average uses during the run-in period.
Night Awakening
Rate of awakening at night because of asthma symptoms
Pulmonary Function: Change in Prebronchodilator FEV1
Mean change in pre-bronchodilator FEV1 - forced expiratory volume in 1 second; a measure of pulmonary function. The treatment effect is the difference in the mean change in between the groups.
Pulmonary Function: Change in Prebronchodilator Forced Vital Capacity
Pulmonary function measured by mean change in Prebronchodilator forced vital capacity from baseline to 24 weeks
Pulmonary Function: Change in Peak Flow Rate
Mean change from baseline to 24 weeks in the peak flow rate - how forceful patient can blow out air
Pulmonary Function: Change in PC20
Mean Change in the dose of methacholine that results in a 20% drop in FEV1
Change in Juniper Asthma Control Score(JACQ)
Mean change. Scores on the JACQ range from 0 to 6, with lower scores indicating better asthma control and 0.5 as the minimal clinically important difference.
Change in Asthma Symptom Utility Index (ASUI)
Mean change. Scores on the ASUI range from 0 to 1, with higher scores indicating less severe asthma.
Change in the Mini-Asthma Quality of Life Questionnaire (Mini-AQLQ)
Mean change. Scores on the Mini-Asthma Quality of Life Questionnaire (mini-AQLQ)range from 1 to 7, with higher scores indicating better quality of life and 0.5 as the minimal clinically important difference.
Change in Medical Outcomes Study Short-Form 36 Score Quality of Life Score: Physical Component
Mean change. Scores on the Medical Outcomes Study Short-Form 36 range from 1 to 100, with higher scores indicating better quality of life and 5 as the minimal clinically important difference.
Change in Medical Outcomes Study Short-Form 36 Quality of Life Score: Mental Component
Mean change. Scores on the Medical Outcomes Study Short-Form 36 range from 1 to 100, with higher scores indicating better quality of life and 5 as the minimal clinically important difference.
Change in Gastric Symptoms: Gastroesophageal Reflux Disease Symptom Assessment Scale Score
Mean change. The Gastroesophageal Reflux Disease Symptom Assessment Scale score ranges from 0 to 3, with lower numbers indicating less distress.
Change in Number of Gastric Symptoms: No. of Symptoms
Mean change

Full Information

First Posted
October 1, 2003
Last Updated
December 17, 2012
Sponsor
Johns Hopkins Bloomberg School of Public Health
Collaborators
American Lung Association Asthma Clinical Research Centers, National Heart, Lung, and Blood Institute (NHLBI)
search

1. Study Identification

Unique Protocol Identification Number
NCT00069823
Brief Title
Study of Acid Reflux in Asthma
Official Title
The Study of Acid Reflux in Asthma
Study Type
Interventional

2. Study Status

Record Verification Date
December 2012
Overall Recruitment Status
Completed
Study Start Date
September 2003 (undefined)
Primary Completion Date
May 2008 (Actual)
Study Completion Date
May 2008 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Johns Hopkins Bloomberg School of Public Health
Collaborators
American Lung Association Asthma Clinical Research Centers, National Heart, Lung, and Blood Institute (NHLBI)

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to determine if subjects with symptomatic asthma who are assigned to treatment with a proton pump inhibitor (PPI) drug such as Nexium have fewer asthma attacks than similar subjects assigned to placebo treatment.
Detailed Description
BACKGROUND: Gastroesophageal reflux (GERD) is frequent in asthmatics with poor asthma control, often occurs without symptoms, and can induce bronchoconstriction. Poorly controlled asthmatics are often treated for GERD with drugs that suppress gastric acid, but this treatment is expensive and the benefit of such treatment is not established. Proton pump inhibitors are a relatively new class of medications that provide highly effective treatment for GERD and associated problems. This success has led many doctors to begin PPI treatment in their asthma patients in an attempt to achieve better asthma control. DESIGN NARRATIVE: The randomized, placebo-controlled trial will enroll 400 asthmatics, ages 18 or older, who have poor asthma control on inhaled steroids, defined on the basis of excessive bronchodilator use, nocturnal awakenings, or frequent exacerbations. Participants will be randomly assigned to treatment with either a proton pump inhibitor, esomeprazole (Nexium) 40 mg twice a day, or matching placebo. The presence, severity, and temporal relationship of GERD to asthma symptoms will be documented with 24 hour ambulatory esophageal potential Hydrogen (pH) probe monitoring, but participants will be enrolled irrespective of the severity of GERD. The primary outcome measure is the proportion of participants who have exacerbations of asthma within a 6-month period defined by asthma diaries and interviews. Secondary outcome measures include asthma symptom and control scores, asthma-specific and generic health-related quality of life, GERD symptoms, health care use, pulmonary function, and airways reactivity. Pre-specified subgroup analyses will be conducted to determine if there are clinical or demographic characteristics that predict benefit from treatment of GERD in asthma.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthma, Lung Diseases, Lung Diseases, Obstructive

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
403 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Esomeprazole
Arm Type
Experimental
Arm Description
Proton pump inhibitor of gastric acid
Arm Title
Placebo for esomeprazoe
Arm Type
Placebo Comparator
Arm Description
Placebo
Intervention Type
Drug
Intervention Name(s)
Esomeprazole
Other Intervention Name(s)
Nexium
Intervention Description
Proton pump inhibitor 40 mg orally twice daily
Intervention Type
Drug
Intervention Name(s)
Placebo proton pump inhibitor
Intervention Description
Placebo proton pump inhibitor
Primary Outcome Measure Information:
Title
Episodes of Poor Asthma Control (EPAC) From Diary Cards, According to Definition That Did Not Include Use of Beta-agonists as a Criterion
Description
Episodes of poor asthma control was defined as any one of the following: 2 consecutive days with a drop in peak flow >=30% of baseline; urgent care for asthma; or new use of oral corticosteroids for asthma
Time Frame
Baseline to 24 Weeks
Secondary Outcome Measure Information:
Title
Exacerbation Components: >=30% Drop in Peak Expiratory Flow on 2 Consecutive Days
Time Frame
Baseline to 24 Weeks
Title
Exacerbation Components: Urgent Care Visit
Time Frame
Measured at Month 6
Title
Exacerbation Components: New Use of Oral Corticosteroids
Time Frame
Baseline to 24 Weeks
Title
Asthma Episodes, According to Definition That Included Increased Use of Beta-agonists
Time Frame
Baseline to 24 Weeks
Title
Use of Rescue Medications
Description
Increase in the use of rescue meds by 4 or more uses on a particular day above the average uses during the run-in period.
Time Frame
Baseline to 24 Weeks
Title
Night Awakening
Description
Rate of awakening at night because of asthma symptoms
Time Frame
Baseline to 24 Weeks
Title
Pulmonary Function: Change in Prebronchodilator FEV1
Description
Mean change in pre-bronchodilator FEV1 - forced expiratory volume in 1 second; a measure of pulmonary function. The treatment effect is the difference in the mean change in between the groups.
Time Frame
Baseline to 24 Weeks
Title
Pulmonary Function: Change in Prebronchodilator Forced Vital Capacity
Description
Pulmonary function measured by mean change in Prebronchodilator forced vital capacity from baseline to 24 weeks
Time Frame
Baseline to 24 Weeks
Title
Pulmonary Function: Change in Peak Flow Rate
Description
Mean change from baseline to 24 weeks in the peak flow rate - how forceful patient can blow out air
Time Frame
Baseline to 24 Weeks
Title
Pulmonary Function: Change in PC20
Description
Mean Change in the dose of methacholine that results in a 20% drop in FEV1
Time Frame
Baseline to 24 Weeks
Title
Change in Juniper Asthma Control Score(JACQ)
Description
Mean change. Scores on the JACQ range from 0 to 6, with lower scores indicating better asthma control and 0.5 as the minimal clinically important difference.
Time Frame
Baseline to 24 Weeks
Title
Change in Asthma Symptom Utility Index (ASUI)
Description
Mean change. Scores on the ASUI range from 0 to 1, with higher scores indicating less severe asthma.
Time Frame
Baseline to 24 Weeks
Title
Change in the Mini-Asthma Quality of Life Questionnaire (Mini-AQLQ)
Description
Mean change. Scores on the Mini-Asthma Quality of Life Questionnaire (mini-AQLQ)range from 1 to 7, with higher scores indicating better quality of life and 0.5 as the minimal clinically important difference.
Time Frame
Baseline to 24 Weeks
Title
Change in Medical Outcomes Study Short-Form 36 Score Quality of Life Score: Physical Component
Description
Mean change. Scores on the Medical Outcomes Study Short-Form 36 range from 1 to 100, with higher scores indicating better quality of life and 5 as the minimal clinically important difference.
Time Frame
Baseline to 24 Weeks
Title
Change in Medical Outcomes Study Short-Form 36 Quality of Life Score: Mental Component
Description
Mean change. Scores on the Medical Outcomes Study Short-Form 36 range from 1 to 100, with higher scores indicating better quality of life and 5 as the minimal clinically important difference.
Time Frame
Baseline to 24 Weeks
Title
Change in Gastric Symptoms: Gastroesophageal Reflux Disease Symptom Assessment Scale Score
Description
Mean change. The Gastroesophageal Reflux Disease Symptom Assessment Scale score ranges from 0 to 3, with lower numbers indicating less distress.
Time Frame
Baseline to 24 Weeks
Title
Change in Number of Gastric Symptoms: No. of Symptoms
Description
Mean change
Time Frame
Baseline to 24 Weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: The general goal of patient selection is to enroll patients for whom asthma physicians might prescribe GERD treatment, but where there is uncertainty whether it might be effective. Age 18 or older Physician diagnosed asthma If amount of air expired in the first second during a forced expiratory maneuver (FEV1) is greater than or equal to 70% predicted normal pre-bronchodilator: demonstrate methacholine 20% from post-diluent baseline (PC20). PC20 less than 16 mg/ml during Visit 1 If FEV1 less than 70% and greater than or equal to 50% predicted normal pre-bronchodilator: demonstrate 12% reversibility during Visit 1 or within past 12 months Currently on stable dose of daily inhaled steroids for asthma control, i.e., inhaled corticosteroid equivalent to 400 ug/day of fluticasone44 or greater for 8 weeks or longer Poor asthma control: Either of the following; a score of 1.5 or greater on the Juniper Asthma Control Questionnaire; two or more episodes of asthma symptoms in the past 12 months with each episode requiring at least one of the following: an emergency department visit, unscheduled physician visit, prednisone course, hospitalization Non-smoker for 6 months or longer Less than 10 pack/year smoking history Exclusion Criteria: Surgery: Previous anti-reflux or peptic ulcer surgery Pulmonary function: FEV1 less than 50% predicted normal pre-bronchodilator GERD Symptoms: Severe reflux constituting a clinical indication for treatment with a PPI or H2 blocker, typically two or more episodes per week of heartburn requiring antacids Other major chronic illnesses; conditions which in the judgment of the Study Physician would interfere with participation in the study, e.g., non-skin cancer, endocrine disease, coronary artery disease, congestive heart failure, stroke, severe hypertension, Type 1 insulin dependent diabetes mellitus, renal failure, liver disorders, immunodeficiency states, major neuropsychiatric disorder Medication use: Anti-reflux medication (proton pump inhibitors or H2 blockers) within 1 month Theophylline, azoles, iron, anti-coagulants, insulin (for Type I diabetes), digitalis, any investigative drugs within 1 month Drug allergy: Previous adverse effects from proton pump inhibitors or methacholine challenge Females of childbearing potential: Pregnant or lactating, unwilling to practice an adequate birth control method (abstinence, combination barrier and spermicide, or hormonal) Inability or unwillingness to provide consent Inability to perform baseline measurements Completion of less than 10 of the last 14 days of screening period diary entry Inability to be contacted by telephone Intention to move out of the area within 6 months
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Robert Wise
Organizational Affiliation
Johns Hopkins University School of Public Health
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Alabama at Birmingham
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35294
Country
United States
Facility Name
University of California, San Diego
City
San Diego
State/Province
California
ZIP/Postal Code
92103
Country
United States
Facility Name
National Jewish Medical and Research Center
City
Denver
State/Province
Colorado
ZIP/Postal Code
80206
Country
United States
Facility Name
Nemours Childrens Clinic
City
Jacksonville
State/Province
Florida
ZIP/Postal Code
32207
Country
United States
Facility Name
University of Miami
City
Miami
State/Province
Florida
ZIP/Postal Code
33136
Country
United States
Facility Name
Emory University
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30322
Country
United States
Facility Name
Northwestern Memorial Hospital
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60611
Country
United States
Facility Name
Indiana University ACRC
City
Indianapolis
State/Province
Indiana
ZIP/Postal Code
46202
Country
United States
Facility Name
LSUHSC Pulmonary Critical Care
City
New Orleans
State/Province
Louisiana
ZIP/Postal Code
70112
Country
United States
Facility Name
University of Minnesota
City
Minneapolis
State/Province
Minnesota
ZIP/Postal Code
55455
Country
United States
Facility Name
Univ of MO Kansas City School of Medicine
City
Kansas City
State/Province
Missouri
ZIP/Postal Code
64108
Country
United States
Facility Name
Washington University School of Medicine
City
St. Louis
State/Province
Missouri
ZIP/Postal Code
63310-1093
Country
United States
Facility Name
North Shore-LIJ Medical Center
City
New Hyde Park
State/Province
New York
ZIP/Postal Code
11040
Country
United States
Facility Name
NYU School of Medicine
City
New York
State/Province
New York
ZIP/Postal Code
10016
Country
United States
Facility Name
New York Medical College
City
Valhalla
State/Province
New York
ZIP/Postal Code
10595
Country
United States
Facility Name
Duke University
City
Durham
State/Province
North Carolina
ZIP/Postal Code
27710
Country
United States
Facility Name
Ohio State University
City
Columbus
State/Province
Ohio
ZIP/Postal Code
43210
Country
United States
Facility Name
Thomas Jefferson Hospital Pulmonary Lab
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19107
Country
United States
Facility Name
Baylor College of Medicine
City
Houston
State/Province
Texas
ZIP/Postal Code
77030-3411
Country
United States
Facility Name
Northern New England Consortium
City
Colchester
State/Province
Vermont
ZIP/Postal Code
05446
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
23026499
Citation
Bime C, Wei CY, Holbrook JT, Sockrider MM, Revicki DA, Wise RA. Asthma symptom utility index: reliability, validity, responsiveness, and the minimal important difference in adult asthmatic patients. J Allergy Clin Immunol. 2012 Nov;130(5):1078-84. doi: 10.1016/j.jaci.2012.07.058. Epub 2012 Sep 29.
Results Reference
derived
PubMed Identifier
22885561
Citation
Bime C, Wei CY, Holbrook J, Smith LJ, Wise RA. Association of dietary soy genistein intake with lung function and asthma control: a post-hoc analysis of patients enrolled in a prospective multicentre clinical trial. Prim Care Respir J. 2012 Dec;21(4):398-404. doi: 10.4104/pcrj.2012.00073.
Results Reference
derived
PubMed Identifier
19661245
Citation
DiMango E, Holbrook JT, Simpson E, Reibman J, Richter J, Narula S, Prusakowski N, Mastronarde JG, Wise RA; American Lung Association Asthma Clinical Research Centers. Effects of asymptomatic proximal and distal gastroesophageal reflux on asthma severity. Am J Respir Crit Care Med. 2009 Nov 1;180(9):809-16. doi: 10.1164/rccm.200904-0625OC. Epub 2009 Aug 6.
Results Reference
derived
PubMed Identifier
19357404
Citation
American Lung Association Asthma Clinical Research Centers; Mastronarde JG, Anthonisen NR, Castro M, Holbrook JT, Leone FT, Teague WG, Wise RA. Efficacy of esomeprazole for treatment of poorly controlled asthma. N Engl J Med. 2009 Apr 9;360(15):1487-99. doi: 10.1056/NEJMoa0806290.
Results Reference
derived

Learn more about this trial

Study of Acid Reflux in Asthma

We'll reach out to this number within 24 hrs